Mark Mercola

Mark Mercola is Professor of Medicine (Cardiovascular) and Professor (By courtesy) in Chemical and Systems Biology at Stanford University. He leads research at the Stanford Cardiovascular Institute and previously held faculty positions at Harvard Medical School and University of California, San Diego. His work focuses on cardiogenesis, patient-specific iPSC modeling, and high-throughput drug discovery.

• Key affiliations: Stanford Cardiovascular Institute, Bio-X, Maternal & Child Health Research Institute
• Advisory roles: Vala Sciences, Regencor, Ted Rogers Centre for Heart Research

Research Interests: Mercola's research bridges cardiovascular biology, stem cell engineering, and drug development. He pioneered Wnt inhibition strategies for cardiogenesis and developed iPSC-cardiomyocyte platforms for disease modeling, safety pharmacology, and target discovery in heart failure. His team explores metabolic maturation of stem cell-derived cardiomyocytes and mechanisms of arrhythmia.

Scientific Awards: NIH MERIT Award for contributions to heart formation research.

Students: Mentored postdoctoral researchers including Xiaozhi Gao, Hiroyuki Inoue, Adithan Kandasamy, and Sarah Sturgill.

Labs & Funding: Operates at Stanford's Cardiovascular Institute and co-established the Conrad Prebys Drug Discovery Center. Funded by NIH, California Institute for Regenerative Medicine, Phospholamban Foundation, and Fondation Leducq.